Cargando…
SUN-170 Development of Type 1 Diabetes Mellitus on Immune Checkpoint Inhibitor
Introduction: Immune checkpoint inhibitors (ICPi) are used to augment the immune response and have led to improved outcomes in various malignancies. With this enhanced immunologic response comes a spectrum of side effects, known as immune-related adverse events (iRAEs). These are most commonly derma...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553242/ http://dx.doi.org/10.1210/js.2019-SUN-170 |